Alpha-1 antitrypsin deficiency (AATD) is an inherited condition affecting production of a protective protein made in the liver. Whilst AATD is best known for causing lung disease, it can also lead to liver complications including cirrhosis and hepatocellular carcinoma. Fatty liver (hepatic steatosis) may occur in people with AATD, but whether the deficiency directly causes fat accumulation remains unclear. Abnormal alpha-1 antitrypsin protein becomes trapped inside liver cells, causing toxic injury, whilst fatty liver often relates to coexisting metabolic factors such as obesity and type 2 diabetes. Understanding this relationship is important for managing liver health in affected individuals.

What Is Alpha-1 Antitrypsin Deficiency?

Alpha-1 antitrypsin deficiency (AATD) is an inherited genetic condition that affects the production of alpha-1 antitrypsin (AAT), a protective protein primarily manufactured in the liver. This protein normally travels through the bloodstream to the lungs, where it protects delicate lung tissue from damage caused by enzymes released during inflammation. When the body produces abnormal or insufficient amounts of AAT, individuals become vulnerable to both lung and liver disease.

The condition follows an autosomal codominant inheritance pattern, meaning that a person inherits one copy of the AAT gene (known as SERPINA1) from each parent. The most common severe deficiency variant is the PiZZ genotype, though numerous other variants exist with varying degrees of protein deficiency. In the UK, AATD affects approximately 1 in 2,000 to 1 in 5,000 individuals, though many cases remain undiagnosed.

Liver involvement in AATD occurs through a different mechanism than lung disease. Abnormal AAT protein molecules become misfolded and accumulate within liver cells (hepatocytes) rather than being properly secreted into the bloodstream. This intracellular accumulation triggers a toxic effect, leading to hepatocyte injury, inflammation, and progressive liver damage. The retained protein forms characteristic periodic acid-Schiff (PAS)-positive, diastase-resistant globules visible on liver biopsy.

Whilst AATD is primarily associated with emphysema in adults and can cause neonatal hepatitis in infants, it can also lead to various forms of chronic liver disease throughout life, including cirrhosis and hepatocellular carcinoma. Fatty liver (hepatic steatosis) may also be present in people with AATD, though it is not clear whether AATD directly causes steatosis or whether it occurs due to common metabolic risk factors such as obesity, type 2 diabetes, and dyslipidaemia. The severity and progression of liver disease vary considerably between individuals, even among those with identical genetic variants. Additional factors—including alcohol consumption, obesity, viral hepatitis, and metabolic syndrome—strongly influence whether and how quickly liver disease develops in people with AATD.

Symptoms and Diagnosis of Liver Disease in Alpha-1 Antitrypsin Deficiency

Clinical presentation of liver disease in AATD varies significantly depending on age and disease stage. In newborns and infants, AATD may present as neonatal jaundice (prolonged beyond two weeks), hepatomegaly (enlarged liver), or cholestasis (impaired bile flow). However, many children with AATD experience spontaneous improvement, with liver function normalising during early childhood.

In adults, liver involvement often develops insidiously. Early stages may be completely asymptomatic, with abnormalities detected only through routine blood tests showing elevated liver enzymes (particularly ALT and AST). As disease progresses, patients may develop:

• Fatigue and general malaise

• Right upper quadrant discomfort or hepatomegaly

• Features of fatty liver disease (hepatic steatosis)

• Signs of cirrhosis including jaundice, ascites (fluid accumulation), peripheral oedema, and spider naevi

• Portal hypertension complications such as variceal bleeding

Diagnostic evaluation begins with measuring serum AAT levels, typically performed when there is unexplained liver disease, particularly in individuals with a family history of AATD or concurrent emphysema. In the UK, AAT levels are usually reported in grams per litre (g/L). Severe deficiency is typically indicated by levels below approximately 0.5–0.6 g/L (normal range approximately 1.0–2.0 g/L; 11 μmol/L is roughly equivalent to 0.57 g/L). Phenotyping or genotyping confirms the specific variant, with PiZZ being most commonly associated with liver disease.

Liver-specific investigations include:

• Liver function tests and coagulation profile

• Ultrasound scanning to assess liver architecture, exclude focal lesions, and evaluate for steatosis (though ultrasound has limited sensitivity for mild steatosis)

• Transient elastography (FibroScan®) to non-invasively assess liver stiffness; if controlled attenuation parameter (CAP) is available, it can estimate hepatic fat content

• Liver biopsy (when diagnosis uncertain) demonstrating characteristic PAS-positive globules and assessing fibrosis stage

• Ultrasound surveillance every six months for hepatocellular carcinoma in people with cirrhosis; alpha-fetoprotein (AFP) may be used as an adjunct depending on local protocols

Regarding fatty liver specifically, hepatic steatosis may occur in people with AATD, but whether AATD directly causes steatosis is unclear. The accumulation of misfolded AAT protein within hepatocytes creates cellular stress, but steatosis in AATD is often associated with coexisting metabolic risk factors such as obesity, type 2 diabetes, and dyslipidaemia. Further research is needed to clarify the relationship between AAT accumulation and fat deposition in the liver.

Treatment and Management Options for Liver Complications

Management of AATD-related liver disease is primarily supportive, as there is currently no specific pharmacological therapy to prevent or reverse AAT protein accumulation in the liver. Treatment strategies focus on monitoring disease progression, managing complications, and addressing modifiable risk factors that may accelerate liver damage.

General liver health measures are essential for all patients with AATD:

• Alcohol abstinence is recommended for people with chronic liver disease or AATD-related liver involvement

• Maintaining healthy body weight – obesity and metabolic syndrome exacerbate fatty liver disease and fibrosis

• Hepatitis A and B vaccination – preventing additional hepatic insults

• Avoiding hepatotoxic medications where possible, including certain herbal supplements

• Regular monitoring of liver function tests and imaging

For patients with fatty liver disease associated with AATD, lifestyle interventions remain the cornerstone of management. A Mediterranean-style diet rich in vegetables, fruits, whole grains, and healthy fats, combined with regular physical activity (at least 150 minutes of moderate-intensity exercise weekly), can reduce hepatic steatosis. Weight loss of 7–10% of body weight has been shown to improve liver histology in metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD), and similar principles apply when steatosis occurs in people with AATD.

Pharmacological interventions for fatty liver in AATD follow general MASLD/NAFLD guidelines, as there are no AATD-specific treatments. According to NICE guidance (NG49), vitamin E may be considered in adults with biopsy-proven non-alcoholic steatohepatitis (NASH) who do not have diabetes or cirrhosis. Vitamin E is used off-label for this indication and should only be started under specialist supervision. Patients should be informed of uncertain long-term safety, including potential risks such as haemorrhagic stroke and prostate cancer. Pioglitazone may also be considered for biopsy-proven NASH under specialist care, with appropriate counselling about risks including weight gain, fluid retention, fractures, and heart failure. Do not self-start supplements without medical advice. Management of associated metabolic conditions (diabetes, dyslipidaemia, hypertension) using standard therapies is important.

If you are prescribed medicines for liver disease or metabolic conditions, report any suspected side effects via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Advanced liver disease management includes:

• Surveillance for hepatocellular carcinoma with ultrasound every six months in people with cirrhosis; AFP may be added as an adjunct according to local protocols

• Endoscopic variceal screening at the time of cirrhosis diagnosis (or according to non-invasive risk criteria such as Baveno VII consensus), with non-selective beta-blockers or endoscopic band ligation as indicated

• Management of ascites, encephalopathy, and other cirrhosis complications according to standard protocols

• Liver transplantation – the definitive treatment for end-stage liver disease, which also corrects the AAT deficiency as the new liver produces normal protein

Emerging therapies under investigation include small interfering RNA (siRNA) treatments designed to reduce production of abnormal AAT protein in the liver, potentially reducing toxic accumulation. However, these remain investigational in the UK and are not yet available in routine clinical practice.

When to Seek Medical Advice

Individuals with known or suspected AATD should maintain regular contact with their healthcare team, typically involving both respiratory and hepatology specialists. However, certain symptoms and situations warrant urgent or prompt medical attention.

Seek immediate medical attention (attend A&E or call 999) if you experience:

• Vomiting blood or passing black, tarry stools (melaena) – suggesting variceal bleeding

• Severe abdominal pain with distension

• Confusion, drowsiness, or personality changes – potential hepatic encephalopathy

• Yellowing of skin or eyes (jaundice) developing rapidly

• Severe breathlessness or chest pain

Contact your GP promptly (within a few days) if you notice:

• New or worsening fatigue that interferes with daily activities

• Unexplained weight loss or loss of appetite

• Mild jaundice or darkening of urine

• Increasing abdominal swelling or ankle oedema

• Easy bruising or bleeding (nosebleeds, bleeding gums)

• Itching (pruritus) without obvious skin cause

• Right upper quadrant discomfort persisting beyond a few days

Routine monitoring is essential even in the absence of symptoms. Patients with confirmed AATD should have:

• Annual liver function tests at minimum, more frequently if abnormal

• Regular clinical review with hepatology services if liver disease is present

• Ultrasound surveillance every six months if cirrhosis is established; AFP may be added depending on local practice

• Lifestyle and vaccination advice from specialist nurses or physicians

Family screening is important, as AATD is inherited. First-degree relatives of affected individuals should be offered genetic counselling and testing, particularly before developing symptoms. Early identification allows for preventive strategies, including smoking avoidance (crucial for preventing lung disease) and liver health optimisation.

Patients should also inform healthcare providers about their AATD diagnosis before starting new medications or undergoing procedures, as this may influence treatment decisions. Pregnancy planning should involve specialist input, primarily for genetic counselling to discuss inheritance and to optimise maternal liver and respiratory health. Most women with AATD have successful pregnancies with appropriate monitoring and coordinated care.

Frequently Asked Questions